Home/Larimar Therapeutics/Michael R. Celano
MR

Michael R. Celano

Chief Financial Officer

Larimar Therapeutics

Larimar Therapeutics Pipeline

DrugIndicationPhase
CTI-1601 (Nomaxofusp)Friedreich's AtaxiaPhase 2
CTI-1601Friedreich's AtaxiaPhase 1